MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation

Reuters

2025/11/07

MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation

Mind Medicine (MindMed) Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581043641"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581043641\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581043641?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581043641","market":"nz","top_or_hot":-1,"title":"MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4gWQ53:1","article_id":"2581043641","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581043641","pubTimestamp":1762464542,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mind Medicine  Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder  and major depressive disorder . The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4547":"WSB热门概念"},"translate_title":"MindMed在新的公司演示中展示了后期管道进展和精神药物里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9},"content_text":"MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    \n\nMind Medicine (MindMed) Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}